primary liver cancer
Conditions
Interventions
Experimental group:balloon-occuluded TACE
Sponsors
Shaanxi Provincial Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The subjects were informed and signed the informed consent form approved by the ethics committee; 2. Aged 18 to 75 years; 3. Primary hepatocellular carcinoma diagnosed according to the diagnostic criteria for liver cancer in the guidelines for the diagnosis and treatment of primary liver cancer promulgated by the National Health and Family Planning Commission in 2019; 4. The Chinese liver cancer stage is IIa-IIIa in the 2019 edition of the Chinese Standards for the Diagnosis and Treatment of Primary Liver Cancer; 5. Good liver function (Child-Pugh A or B7 grade) or ALBI grade 1/2; 6. Performance status ECOG score of 0 or 1.
Exclusion criteria
Exclusion criteria: 1. Extrahepatic metastasis occurs; 2. Any contraindications to transarterial chemoembolization; 3. Advanced liver disease (bilirubin>2.5mg/dl, transaminase>5 times the upper limit of normal); 4. Renal failure or renal insufficiency (creatinine>2mg/L); 5. The subject is unable to perform MRI examination; 6. Pregnant, lactating women or subjects who plan to become pregnant during treatment and within 12 months after the end of treatment; 7. Women of childbearing age cannot receive reliable contraception during treatment and within 12 months after treatment; 8. The subject is currently participating in the clinical research of other experimental drugs or devices; 9. The investigator believes that the patient is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| disease-free time;overall survival; | — |
Countries
China
Contacts
Public ContactLi Zhubin
Shaanxi Provincial Cancer Hospital
Outcome results
None listed